Freedom Capital Markets has reduced its price target for Pfizer stock from $38 to $33, citing the “unwinding” of COVID-related revenues. This suggests concerns about Pfizer’s future performance now that demand for COVID vaccines and treatments is decreasing. The new target reflects an anticipated decline in earnings and overall market sentiment towards the company as its reliance on COVID-related products diminishes.
